| MATERIALS AND LINKS Meeting Information: Agenda Participant List Presentations: Veronica Miller Nina Mani Jamie Siegel Mark Antell Kenneth Sherman Filip Josephson Jeffrey Murray Michelle Berrey Diana Brainard |
The historical cohort of bleeding disorder patients exposed to contaminated blood products from the late 1970s to 1990 is a population currently experiencing high rates of liver-related morbidity and mortality due to hepatitis C viral (HCV) infection. The October 17, 2011 meeting sponsored by the Forum was the first in a series of meetings that will try and address issues associated with providing access to, if indicated, combination interferon-free experimental direct acting antivirals (DAAs).
Meeting participants included representatives from regulatory agencies, academia, hemophilia treatment centers, non-profits associated with database management for those affected with bleeding and blood clotting disorders, community medical practitioners, patient advocates and pharmaceutical companies.
Objectives:
1. Discuss safety issues that should be considered
2. Discuss clinical trial entry criteria and diagnostic tests used
in this population
3. Discuss possible sites for trials and the specialists who should be involved
Status:
The meeting was held on Monday, October 17, 2011 at UC Washington Center, Washington DC.